10.3389/fpsyg.2012.00132

Vollständiger Abstract

Worum geht es in dieser Arbeit?

<h4>Background</h4>This study aimed to investigate recurrence patterns and survival outcomes in Chinese patients with AM who received postoperative adjuvant High-dose interferon (HD-IFN), and to assess how treatment duration and the interval between surgery and therapy initiation relate to recurrence and survival.<h4>Methods</h4>A multi-center, retrospective cohort study involving 171 patients with AM who received postoperative adjuvant HD-IFN therapy between January 2012 and March 2025 was conducted at five melanoma diagnostic and treatment centers across China.<h4>Results</h4>The median follow-up duration was 75.7 months. Median recurrence-free survival (RFS) and overall survival (OS) were 37.5 and 93.7 months, respectively. Stratified by recurrence risk, patients in the low-risk, high-risk, and very high-risk groups had median RFS of 64.1, 31.6, and 13.8 months (<i>P</i> = 0.035), and median OS of 131.9, 82.1, and 61.9 months, respectively (<i>P</i> = 0.027).<h4>Conclusion</h4>Results show that full-course HD-IFN treatment is statistically associated with improved survival in high-risk and very high-risk subgroups, whereas the timing of HD-IFN initiation within 3 months after surgery makes no significant difference to prognosis.

Abstract: PubMed · Datensatz